Lilly (Eli) (LLY) Q3 2025 10-Q Quarterly Report
Lilly (Eli) (LLY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Lilly (Eli) Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Cash and cash equivalents $9.79B as of Sept 30, 2025 vs $3.27B at Dec 31, 2024
- • Total debt $42.51B as of Sept 30, 2025, up $8.86B from $33.64B at Dec 31, 2024
- • Capital expenditures and contract manufacturing agreements increased for capacity expansion, risking $9B in minimum purchase commitments
- • Share repurchases $2.60B YTD under $15B program; $12.40B remaining as of Sept 30, 2025
- • No updated revenue, profit, or margin data presented; management notes foreign exchange, economic environment, and geopolitical risks impacting outlook
Risk Factors
- • New litigation charge from acquisition of Verve triggered asset impairment and restructuring charges of $365M for Q3 2025, up from $82M prior year
- • Effective tax rate decreased to 22.8% in Q3 2025 from 38.9% in Q3 2024, impacted by lower non-deductible acquired IPR&D charges
- • Litigation charge and acquisition/integration costs of Verve represent most impactful legal risk affecting operational costs
- • Revenue growth driven by strong volume increase in Mounjaro (+109%) and Zepbound (+185%) reflecting competitive market demand
- • Cash and equivalents, operating cash flow, and borrowings sufficient to fund capital requirements, maintaining liquidity position
Lilly (Eli) Q3 2025 Quarterly FinancialsXBRL
Revenue
$17.6B
▲ +53.9% YoY▲ +13.1% QoQ
Net Income
$5.6B
▲ +475.3% YoY▼ -1.4% QoQ
Net Margin
31.7%
▲ +2323bp YoY▼ -467bp QoQ
Source: XBRL data from Lilly (Eli) Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Lilly (Eli) Quarterly Reports
Get deeper insights on Lilly (Eli)
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.